Maravai LifeSciences Holdings, Inc. — Form 8-K Summary
Business Context and Reporting Period
Maravai LifeSciences Holdings, Inc. filed a Form 8-K reporting results from its 2024 Annual Meeting of Shareholders held on May 23, 2024. The report was signed on May 28, 2024. The filing concerns corporate governance matters and does not report quarterly or annual financial results.
Key Financial and Capitalization Information
- As of the March 25, 2024 record date, the Company had 251,748,827 common shares outstanding, comprising 132,654,801 Class A shares and 119,094,026 Class B shares.
- Shares present in person or by proxy totaled 236,931,940, constituting a quorum.
- The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics.
Voting Results and Material Changes
- Director elections: Benjamin Daverman, Susannah Gray, Carl Hull, and Constantine Mihas were elected to three-year terms expiring at the 2027 annual meeting, subject to earlier death, resignation, removal, or successor qualification.
- Votes for the elected nominees ranged from 191,415,297 to 196,078,626; withheld votes ranged from 31,324,554.90 to 35,987,883.90; broker non-votes totaled 9,528,759.10 for each nominee, as reported in the filing.
- Independent auditor: Shareholders ratified Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2024, with 236,288,478 votes for, 268,742 against, and 374,720 abstentions.
- Executive compensation: Shareholders approved, on a non-binding advisory basis, the compensation of the named executive officers. The vote was 223,303,654.90 for, 4,747,004 against, 200,454 abstentions, and 8,680,827.10 broker non-votes.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no management guidance, operating outlook, risk-factor updates, contingencies, or unusual financial items. Its principal implications are the continuation of the elected directors, ratification of the auditor, and advisory approval of executive compensation.
Important Facts to Verify
- Confirm the elected directors’ terms and any subsequent changes to board composition.
- Verify Ernst & Young LLP’s appointment and review the auditor’s subsequent filings or reports for the 2024 fiscal year.
- Review the Company’s proxy statement for detailed director biographies, executive compensation disclosures, and voting mechanics.
- Reconcile the fractional vote figures and share counts against the Company’s official voting records if precise vote totals are material.